Evidence map›Paper›PMID 38347332›Full record

ArticleAnnals of surgical oncology2024

Early Onset Intrahepatic Cholangiocarcinoma: Clinical Characteristics, Oncological Outcomes, and Genomic/Transcriptomic Features.

Diamantis I Tsilimigras, Xu Han, Alfredo Guglielmi, Luca Aldrighetti, Matthew Weiss, Todd W Bauer, Sorin Alexandrescu, George A Poultsides, Shishir K Maithel, Hugo P Marques and 11 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 18 institutions in 10 countries.

Diamantis I Tsilimigras *Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
Xu Han *Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
Alfredo GuglielmiDepartment of Surgery, University of Verona, Verona, Italy.
Luca AldrighettiDepartment of Surgery, Ospedale San Raffaele, Milan, Italy.
Matthew WeissDepartment of Surgery, Johns Hopkins Hospital, Baltimore, MD, USA.
Todd W BauerDepartment of Surgery, University of Virginia, Charlottesville, VA, USA.
Sorin AlexandrescuDepartment of Surgery, Fundeni Clinical Institute, Bucharest, Romania.
George A PoultsidesDepartment of Surgery, Stanford University, Stanford, CA, USA.
Shishir K MaithelDepartment of Surgery, Emory University, Atlanta, GA, USA.
Hugo P MarquesDepartment of Surgery, Curry Cabral Hospital, Lisbon, Portugal.
Guillaume MartelDepartment of Surgery, University of Ottawa, Ottawa, Canada.
Carlo PulitanoDepartment of Surgery, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia.
Feng ShenDepartment of Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
François ChaucyDepartment of Hepatobiliopancreatic Surgery and Liver Transplantation, AP-HP, Beaujon Hospital, Clichy, France.
Bas Groot KoerkampDepartment of Surgery, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Itaru EndoDepartment of Gastroenterological Surgery, Yokohama City University School of Medicine, Yokohama, Japan.
Kazunari SasakiDepartment of Surgery, Stanford University, Stanford, CA, USA.
Federico AucejoDepartment of General Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, USA.
Xu-Feng ZhangDepartment of Hepatobiliary Surgery, Institute of Advanced Surgical Technology and Engineering, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Hua ZhuDepartment of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
Timothy M PawlikDepartment of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA. tim.pawlik@osumc.edu.ORCID http://orcid.org/0000-0002-7994-9870
The Ohio State University Wexner Medical Center · USStanford University · USCleveland Clinic · USEmory University · USErasmus University Rotterdam · NLFirst Affiliated Hospital of Xi'an Jiaotong University · CNFudan University · CNHôpital Beaujon · FRHospital Curry Cabral · PTInstitutul Clinic Fundeni · ROIRCCS Ospedale San Raffaele · ITJohns Hopkins Hospital · USSecond Military Medical University · CNThe University of Sydney · AUUniversity of Ottawa · CAUniversity of Verona · ITUniversity of Virginia · USYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionData on clinical characteristics and disease-specific prognosis among patients with early onset intrahepatic cholangiocarcinoma (ICC) are currently limited.

methodsPatients undergoing hepatectomy for ICC between 2000 and 2020 were identified by using a multi-institutional database. The association of early (≤50 years) versus typical onset (>50 years) ICC with recurrence-free (RFS) and disease-specific survival (DSS) was assessed in the multi-institutional database and validated in an external cohort. The genomic and transcriptomic profiles of early versus late onset ICC were analyzed by using the Total Cancer Genome Atlas (TCGA) and Memorial Sloan Kettering Cancer Center databases.

resultsAmong 971 patients undergoing resection for ICC, 22.7% (n = 220) had early-onset ICC. Patients with early-onset ICC had worse 5-year RFS (24.1% vs. 29.7%, p < 0.05) and DSS (36.5% vs. 48.9%, p = 0.03) compared with patients with typical onset ICC despite having earlier T-stage tumors and lower rates of microvascular invasion. In the validation cohort, patients with early-onset ICC had worse 5-year RFS (7.4% vs. 20.5%, p = 0.002) compared with individuals with typical onset ICC. Using the TCGA cohort, 652 and 266 genes were found to be upregulated (including ATP8A2) and downregulated (including UTY and KDM5D) in early versus typical onset ICC, respectively. Genes frequently implicated as oncogenic drivers, including CDKN2A, IDH1, BRAF, and FGFR2 were infrequently mutated in the early-onset ICC patients.

conclusionsEarly-onset ICC has distinct clinical and genomic/transcriptomic features. Morphologic and clinicopathologic characteristics were unable to fully explain differences in outcomes among early versus typical onset ICC patients. The current study offers a preliminary landscape of the molecular features of early-onset ICC.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaBile Ducts, IntrahepaticGene Expression ProfilingGenomicsHepatectomyHistone DemethylasesHumansMinor Histocompatibility AntigensPrognosisHistone DemethylasesKDM5D protein, humanMinor Histocompatibility AntigensEarly onsetGeneticIntrahepatic cholangiocarcinomaPrognosisResection

Identifiers

PMID38347332
PMCPMC10997729
OpenAlexW4391755866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.